Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Anti-NMDA Receptor Encephalitis
Transcript of Anti-NMDA Receptor Encephalitis
Ultimately auto-antibodies with cross reactivity to receptors are produced.
Often the patient has a teratoma which is an encapsulated tumor with more than one germ cell layer.
The acute inflammatory response in those with a tumor or may result in breakdown of BBB causing passive diffusion of the antibodies into the brain.
Increase in blood pressure may sometimes cause extravasation into CSF.
Some patients have intact BBB and no teratomas but high conc. of antibodies in intrathecal space(Dalmau et. al).
Accounts for around 1% of encephalitides of unknown etiology.
Review done in Lancet(Dalmau et. al) of 100 cases showed 91 of 100 cases were women with a mean age of 23.
58 had a tumor predominantly an ovarian teratoma.
Showed Asian and African populations are more likely to get conditon.
Males may have testicular germ cell tumor, mediatinal teratomas or Hodgkin's Lymphoma.
only 5 cases were > 45 years of age.
Labs and Tests
Critical for synaptic plasticity, learning, and memory.
It is both ligand gated and voltage dependent.
It requires co-activation by both glutamate and either D-serine or glycine.
Acts via calcium flux through receptor.
Cytokine Release Syndrome
Tumor Lysis Syndrome
Progressive Multifocal Leukoencephalopathy
An alkylating agent which cross-links DNA
s/e include: chemo-induced N/V hemorrhagic cystitis(prevented by giving mesna), bone marrow supression, darkening of skin and nails
Carcinogenic and may cause transitional cell carcinoma of the bladder or AML
A prodromal phase of non-specific viral illness(fever, headaches, muscle pains)
Psychiatric disturbance with schizophrenic-like manifestations(hallucinations, disorganized thinking, bizarre behavior, delusions).
most often anterograde amnesia
Decreased LOC and low Glasgow coma scale
stupor with catatonic feature
Autonomic instability: wide BP fluctuation, hypoventilation, bradycardia, tachycardia
Autoantibodies to NMDA receptors in the brain.
Bind to NR1 subunit of NMDA receptor.
May reduce number of receptors via internalization once antibody binds.
May be a direct antagonist of NMDA receptor to prevent binding.
May recruit complement type cascade(less likely as would see more neuronal death).
Chimeric monoclonal antibody against the CD20 protein on the surface of immune B cells which produce antibodies
CD20 on immature B cells but not terminally differentiated plasma cells.
Receptor may modulate Ca+2 influx across membrane and can effectively kill the cell
Treatment and Management
CSF lymphocytic pleocytosis or oligoclonal bands.
EEG with infrequent epileptic activity, but frequent slow, disorganized activity.
Brain MRI often normal but may show transient FLAIR or contrast enhancing abnormalities in cortical or subcortical regions.
Most specific and sensitive tests is Detection of antibodies to NR1 subunit of NMDA-R in serum or CSF.
Titer of CSF antibodies correlates more closely with clinical outcome
Neuroleptic Malignant Syndrome
Other psych disorders or encephalitides
Patients with a tumor have best prognosis with lower chance of relapse
resected tumor removes source of antibodies
After removal IVIG .4g/kg daily for five days and methylprednisolone 1g daily for 5 days
After 10 days if only minimal improvement start rituximab 375 mg IV every week for 4 weeks combined with cyclophosphamide 750mg in monthly cycles
Treatment may often take up to 18 months for substantial recovery
Cognitive impairments often more severe and permanent when there is delay in diagnosis as patients may often see psychiatrists before neurologist
Brain on Fire:
My Month of Madness
By: Susannah Callahan
Dalmau, Josep; Gleichman, Amy J; Hughes, Ethan G; Rossi, et al (2008). "Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies". The Lancet Neurology 7 (12): 1091–8.
Dalmau, Josep; Tüzün, Erdem; Wu, Hai-yan et al. (2007). "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma". Annals of Neurology 61 (1): 25–36.
Titulaer, Maarten J; McCracken, Lindseyet al. (2013). "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study". The Lancet Neurology 12 (2): 157–65.
Hacohen Y, Wright S, Waters P, et al. "Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens." J Neurol Neurosurg Psychiatry 2013; 84:748.
Vitaliani R, Mason W, Ances B, et al. "Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma." Ann Neurol 2005; 58:594.
Dalmau J, Lancaster E, Martinez-Hernandez E, et al. "Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis." Lancet Neurol 2011; 10:63.
Zandi MS, Irani SR, Follows G, et al. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. Neurology 2009; 73:2039.
FLAIR image of anti-NMDA